Assertio Therapeutics sells world rights of Gralise to Alvogen.
Assertio Therapeutics, Inc.announced it has entered into an agreement with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated with the product Gralise (gabapentin). The agreement is expected to close in early January 2020, subject to regulatory approval.
Under the terms of the agreement, Alvogen will pay Assertio a total value of $127.5 million. This includes $75 million in cash upon closing and the balance payable in the form of a royalty on the first $70 million in Gralise net sales. Both companies expect the majority of the royalties to be paid in the first calendar year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins